Neuronetics (NSDQ:STIM) shares were down today on third-quarter results that came up short of the consensus forecast. The Malvern, Pa.–based company — which makes a transcranial magnetic stimulation system to treat major depressive disorder — posted losses of -$6.9 million, or -37¢ per share, on sales of $16 million for the three months ended Sept. 30, […]
Neuronetics inks deal with TMS provider for NeuroStar depression device
Neuronetics (NSDQ:STIM) said today that it entered into a partnership with Success TMS to offer Neuronetics’ NeuroStar advanced therapy system as its preferred transcranial magnetic stimulation device across six states. The NeuroStar system is designed to use strong magnetic fields to stimulate areas of the brain associated with mood in the treatment of patients with […]
Neuronetics updates patient tracking system
Neuronetics (NSDQ:STIM) today announced the launch of a patient data management system designed to simplify administrative tasks and enable doctors to spend more time on patient care. The TrakStar Plus system builds on the Malvern, Penn.-based company’s TrakStar Cloud platform, designed to help physicians track patients implanted with Neuronetics’ NeuroStar device. Neurostar uses strong magnetic […]
Cutera snags Vyaire Medical’s Mowry for CEO | Personnel Moves, July 9, 2019
Cutera (NSDQ:CUTR) said today that it snagged Vyaire Medical CEO David Mowry to be its new CEO, effective immediately. The aesthetic device maker in January fired president & CEO James Reinstein after the company missed expectations for its 2018 top line, naming COO Jason Richey as interim chief executive. Mowry led Tornier to a $3.3 billion […]
Globus Medical gains on Street-beating prelims | Wall Street Beat
Globus Medical (NYSE:GMED) shares closed up yesterday after the orthopedics company reported preliminary fourth-quarter and 2018 sales numbers that beat the consensus forecast on Wall Street. Audubon, Pa.-based Globus said it expects to post Q4 revenues of $195.5 million and full-year sales of $712.5 million; analysts on The Street were looking for quarterly sales of $188.2 million and […]
Neuronetics reels in $108m from IPO
Neuronetics (NSDQ:STIM) this week closed its initial public offering, according to a document filed with the SEC. The Malvern, Penn.-based company said that it offered 6,325,000 shares of its common stock and that underwriters exercised in full their option to buy additional shares, bringing the total proceeds from the IPO to $107.5 million. Shares began trading […]
Neuronetics prices $94m IPO
Neuronetics today priced its upcoming initial public offering, expecting to raise approximately $93.5 million to support its NeuroStar transcranial magnetic stimulation system designed to treat patients with major depressive disorder who aren’t responding to medication. The Malvern, Penn.-based company said it is looking to float 5.5 million shares of its common stock at $17 per share […]
Neuronetics adds up-to $12m over-allotment option to pending IPO
Neuronetics this week added an underwriter’s option to its initial public offering, which could bring in between $10.5 million and $12 million if fully exercised, and gave a rough price range for the offering. The Malvern, Penn.-based company said it is filing for the public offering to expand its commercialization efforts for the NeuroStar transcranial magnetic […]
Neuronetics files for $86m IPO
Neuronetics yesterday registered an initial public offering worth more than $86 million with the U.S. Security & Exchange Commission, saying it plans to expand its commercialization efforts for the NeuroStar transcranial magnetic stimulation device for treating depression. The NeuroStar device uses MRI-strength magnetic fields to stimulate specific areas of the brain associated with mood. The device initially […]
Neuronetics raises $34m for anti-depression device
Neuronetics said it raised $34.3 million in an equity offering slated to help broaden the use of its anti-depression device that relies on magnetic stimulation of the brain.
Neuronetics launches postpartum depression trial
Neuronetics said it’s enrolled 5 patients in an open-label trial of its transcranial magnetic stimulation device for treating postpartum depression.
The Malvern, Pa.-based medical device company makes the NeuroStar TMS device, designed to use a focused magnetic field to stimulate brain cells to treat depression.
MassDevice Network
@MassDevice
LinkedIn
YouTube